Zejing Pharmaceutical (688266.SH): Human thyrotropin beta for injection approved for marketing

Zhitongcaijing · 3d ago

Zhitong Financial App News, Zejing Pharmaceutical (688266.SH) issued an announcement. On January 8, 2026, the company received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and a new drug marketing application for injectable human thyrotropin beta (former name: injectable recombinant human thyroid-stimulating hormone, trademark: zesunin®) was approved. The indications approved this time are: “For collaborative diagnosis of patients with differentiated thyroid cancer in follow-up after total thyroidectomy or near total thyroidectomy for testing with or without radiology “Iodine (131I) whole-body imaging (WBS) examination”. Injectable human thyroxine beta is the first innovative product approved for accurate evaluation of differentiated thyroid cancer after surgery in China.